SPDR S&P Pharmaceuticals ETF (XPH)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in SPDR S&P Pharmaceuticals ETF, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

SPDR S&P Pharmaceuticals ETF (XPH) has returned -3.32% so far this year and 24.45% over the past 12 months. Over the last ten years, XPH has returned 3.82% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since Jun 22, 2006, XPH's average daily return is +0.04%, while the average monthly return is +0.82%. At this rate, your investment would double in approximately 7.1 years.

Historically, 59% of months were positive and 41% were negative. The best month was Apr 2020 with a return of +16.4%, while the worst month was Sep 2015 at -18.8%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 6 months.

On a daily basis, XPH closed higher 53% of trading days. The best single day was Oct 13, 2008 with a return of +10.9%, while the worst single day was Mar 16, 2020 at -11.9%.

SPDR S&P Pharmaceuticals ETF has an annualized alpha of 2.27%, beta of 0.79, and R² of 0.50 versus S&P 500 Index. Calculated based on daily prices since June 23, 2006.

• This ETF participated in 95.28% of S&P 500 Index downside but only 93.28% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.50 means the benchmark explains less than half of this ETF's behavior — treat beta with caution or consider switching to a more representative benchmark.

XPH has an expense ratio of 0.35%, placing it in the medium range.

XPH ranks 55 for risk / return — on par with similar ETFs. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for SPDR S&P Pharmaceuticals ETF (XPH) and compare them to a chosen benchmark (S&P 500 Index).

SPDR S&P Pharmaceuticals ETF provided a 0.69% dividend yield over the last twelve months, with an annual payout of $0.37 per share.

The table displays the monthly dividend distributions for SPDR S&P Pharmaceuticals ETF. The dividends shown in the table have been adjusted to account for any splits that may have occurred.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the SPDR S&P Pharmaceuticals ETF. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the SPDR S&P Pharmaceuticals ETF was 48.03%, occurring on Mar 23, 2020. Recovery took 1446 trading sessions.

The current SPDR S&P Pharmaceuticals ETF drawdown is 7.29%.

The chart below shows the rolling one-month volatility.